UPDATED: Horizon nabs another rare disease pipeline for the portfolio in $3B buyout. And AstraZeneca — a future rival — is getting about $780M of that
Seven months after scoring its first FDA approval, AstraZeneca spinoff Viela is being bought out for $3 billion.
Horizon announced this morning that it is scooping up the company and its drug Uplizna, adding another rare disease drug to the portfolio. Viela won an approval for their therapy last summer as a rival to Alexion’s Soliris — now being bought out by AstraZeneca — for patients suffering from neuromyelitis optica spectrum disorder (NMOSD). Roche followed soon after with its own OK for their drug Enspryng, which hit the market at a price of $220,000 for the first year of treatment.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.